PEDAL Study: Prospera™ dd-cfDNA use in post-rejection monitoring

Genetics in Practice - Case Spotlight: ADPKD with Dr. Rastogi

Genetics in Practice | Case Spotlight: ADPKD with Dr. Rastogi

Genetics in Practice | Case Spotlight: FSGS with Dr. Rastogi

Explore a FSFS case with Dr. Rastogi and see how Renasight guided care decisions

Genetics in Practice | Case Spotlight: FSGS w/ family history with Dr. Eftekhari

Explore a FSGS case with family history with Dr. Eftekhari and see how Renasight guided care decisions

Combating Rejection with DNA Testing

Illuminating the CKD patient journey: Clinicogenomic data reshapes research & drug discovery

Chronic kidney disease (CKD) presents complex diagnostic and therapeutic challenges due to its heterogeneity and progressive nature. In this webinar, we explore how integrating genetic testing with re

One Year of Prospera Heart with DQS

Advancing ADPKD Diagnosis and Management: A Case-Based Approach to Understanding the Latest Guideline & the Role of Genetic Testing

Renasight - Variants of Uncertain Significance Video

This brief video will introduce you to genetic variant classification, with a focus on variants of uncertain significance (VUSes)

ISHLT 2025 clinical use of DQS Brent Lampert

Dr Lampert from Ohio State shares three key scenarios where DQS has added clinical value above and beyond traditional dd-cfDNA testing.

ISHLT 2025 Trifecta Heart with DQS Phil Halloran

Dr Phil Halloran walks through initial data from the Trifecta Heart study highlighting the correlation between dd-cfDNA fraction and DQS with MMDx.

ISHLT 2025 clinical use of DQS Roopa Rao

Dr Roopa Rao from IU Health shares her experience with 2 unique cases where Prospera Heart with DQS was key to their clinical care.

ISHLT 2025 DQS Background Michael Olympios

Natera's medical director, Michael Olympios, introduces the concept of donor quantity score and highlights key supportive evidence.